Momenta Pharmaceuticals (MNTA) 10.71 $MNTA
Momenta Pharmaceuticals Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Jul 31, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the second quarter ended June 30, 2014.
Momenta Pharmaceuticals to Webcast Presentation at the Canaccord Genuity Growth Conference
GlobeNewswire - Wed Jul 30, 3:14PM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the Canaccord Genuity Growth Conference will be webcast on Thursday, August 14 at 4:00 p.m. ET.
World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others) 2013-2017
M2 - Wed Jul 23, 3:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpvpdw/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - Biosimilars Pipeline by Company and Product Type - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/tp...rld_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Momenta Pharmaceuticals Announces Date of Second Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Wed Jul 16, 3:52AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the second quarter ended June 30, 2014 before the U.S. financial markets open on Thursday, July 31, 2014.
Teva's Contraceptive Gets Positive CHMP Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:00PM CDT
Teva Pharmaceutical Industries Ltd.'s (TEVA) extended-regimen oral contraceptive, Seasonique got a positive recommendation from theCommittee for Medicinal Products for Human Use.
Buy, Sell, or Hold This Generic Pharma Titan?
Chuck Saletta, The Motley Fool - Motley Fool - Fri Jun 27, 4:00PM CDT
Teva Pharmaceuticals is the world's largest generic-drug maker. Somewhat ironically for a company that specializes in generics, its business is struggling at the moment as its own blockbuster patent-protected drug, Copaxone, just lost its patent...
Earnings Estimates Moving Higher for Momenta Pharmaceuticals (MNTA): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 7:42AM CDT
Momenta Pharmaceuticals has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front
Battle of the Biotech Bands - A Great Time for a Great Cause
PR Newswire - Thu Jun 12, 1:45PM CDT
BioBridges, a leading clinical contract consulting company, is so proud to have joined the sponsorship of the second annual Battle of the Biotech Bands. BoBB is a fun, community-driven, networking event with fundraising efforts supporting the charitable foundation affiliated with each biotech band.
Pipeline Progress at Momenta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 09, 5:35PM CDT
Momenta Pharmaceuticals, Inc. (MNTA) recently got some good news when the company received Orphan Drug Designation for its oncology candidate, necuparanib, from the FDA.
Momenta Pharmaceuticals to Webcast Presentation at the Wells Fargo Healthcare Conference
GlobeNewswire - Mon Jun 09, 3:05PM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the Wells Fargo Healthcare Conference will be webcast on Tuesday, June 17 at 9:25 a.m. ET.
The World Market for Biosimilars 2013-2017 - EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies
M2 - Fri Jun 06, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7brbq6/the_world_market) has announced the addition of the "The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition" report to their offering. The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) - Biosimilars Pipeline by Company and Product Type As part of its coverage, the following companies were profiled: - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/7b...rld_market
Momenta Pharmaceuticals wins US FDA's orphan drug status for necuparanib for treating pancreatic cancer
M2 - Fri Jun 06, 3:16AM CDT
Biotechnology company Momenta Pharmaceuticals (NasdaqGS:MNTA) revealed on Thursday the receipt of orphan drug designation from the US Food and Drug Administration (FDA) for its novel oncology candidate, necuparanib (formerly M402), for the treatment of pancreatic cancer.
Momenta Pharmaceuticals Receives Orphan Drug Designation for Necuparanib (Formerly M402) in Pancreatic Cancer
GlobeNewswire - Thu Jun 05, 7:10AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that its novel oncology candidate, necuparanib (formerly M402), has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.
Biotech Stocks Technical Data -- Research on Dynavax Technologies, Ironwood Pharma, Rigel Pharma, and Momenta Pharma
PR Newswire - Tue Jun 03, 6:30AM CDT
On Monday, June 02, 2014, the NASDAQ Composite ended at 4,237.20, down 0.13%, the Dow Jones Industrial Average finished the day 0.16% higher at 16,743.63, and the S&P 500 closed at 1,924.97, up 0.07%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 691.40, up 0.17%, and the index has advanced 3.37% in the last one month. Investor-Edge has initiated coverage on the following equities: Dynavax Technologies Corp. (NASDAQ: DVAX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA). Free technical research on DVAX, IRWD, RIGL and MNTA can be downloaded upon signing up at:
Supreme Court + Risky Drug Launch = Billions at Stake
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Fri May 30, 10:35AM CDT
Teva Pharmaceutical no stranger to the courts, is on a bit of a losing streak trying to protect its lead multiple sclerosis drug, Copaxone. Because the company focuses on low margin generic drugs, its branded MS drug brings in a roughly fifth of...
Momenta Pharmaceuticals Has Returned 14.0% Since SmarTrend Recommendation (MNTA)
Comtex SmarTrend(R) - Tue May 27, 5:09PM CDT
SmarTrend identified a Downtrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on March 3rd, 2014 at $14.80. In approximately 3 months, Momenta Pharmaceuticals has returned 13.96% as of today's recent price of $12.73.
Teva Pharmaceutical Industries Ltd. Gets a Taste of its Own Medicine
Brian Orelli, The Motley Fool - Motley Fool - Thu May 22, 5:30PM CDT
Last week, Teva Pharmaceutical failed in another effort to block generic versions of its multiple sclerosis drug Copaxone from being approved by the Food and Drug Administration. The company, which also makes generic drugs, requested that a judge...
Insider Trading Alert - MNTA, CSCO And ANSS Traded By Insiders
at The Street - Thu May 22, 10:45AM CDT
Stocks with insider trader activity include MNTA, CSCO and ANSS
Momenta Pharmaceuticals Slumps: MNTA Falls 16.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:55AM CDT
Momenta Pharma saw a big move last session, as the company’s shares fell by nearly 17% on the day.
Momenta Pharmaceuticals Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Jul 31, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the second quarter ended June 30, 2014.
Momenta Pharmaceuticals to Webcast Presentation at the Canaccord Genuity Growth Conference
GlobeNewswire - Wed Jul 30, 3:14PM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the Canaccord Genuity Growth Conference will be webcast on Thursday, August 14 at 4:00 p.m. ET.
World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others) 2013-2017
M2 - Wed Jul 23, 3:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpvpdw/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - Biosimilars Pipeline by Company and Product Type - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/tp...rld_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Momenta Pharmaceuticals Announces Date of Second Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Wed Jul 16, 3:52AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the second quarter ended June 30, 2014 before the U.S. financial markets open on Thursday, July 31, 2014.
Teva's Contraceptive Gets Positive CHMP Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:00PM CDT
Teva Pharmaceutical Industries Ltd.'s (TEVA) extended-regimen oral contraceptive, Seasonique got a positive recommendation from theCommittee for Medicinal Products for Human Use.
Buy, Sell, or Hold This Generic Pharma Titan?
Chuck Saletta, The Motley Fool - Motley Fool - Fri Jun 27, 4:00PM CDT
Teva Pharmaceuticals is the world's largest generic-drug maker. Somewhat ironically for a company that specializes in generics, its business is struggling at the moment as its own blockbuster patent-protected drug, Copaxone, just lost its patent...
Earnings Estimates Moving Higher for Momenta Pharmaceuticals (MNTA): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 7:42AM CDT
Momenta Pharmaceuticals has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front
Battle of the Biotech Bands - A Great Time for a Great Cause
PR Newswire - Thu Jun 12, 1:45PM CDT
BioBridges, a leading clinical contract consulting company, is so proud to have joined the sponsorship of the second annual Battle of the Biotech Bands. BoBB is a fun, community-driven, networking event with fundraising efforts supporting the charitable foundation affiliated with each biotech band.
Pipeline Progress at Momenta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 09, 5:35PM CDT
Momenta Pharmaceuticals, Inc. (MNTA) recently got some good news when the company received Orphan Drug Designation for its oncology candidate, necuparanib, from the FDA.
Momenta Pharmaceuticals to Webcast Presentation at the Wells Fargo Healthcare Conference
GlobeNewswire - Mon Jun 09, 3:05PM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the Wells Fargo Healthcare Conference will be webcast on Tuesday, June 17 at 9:25 a.m. ET.
The World Market for Biosimilars 2013-2017 - EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies
M2 - Fri Jun 06, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7brbq6/the_world_market) has announced the addition of the "The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition" report to their offering. The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) - Biosimilars Pipeline by Company and Product Type As part of its coverage, the following companies were profiled: - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/7b...rld_market
Momenta Pharmaceuticals wins US FDA's orphan drug status for necuparanib for treating pancreatic cancer
M2 - Fri Jun 06, 3:16AM CDT
Biotechnology company Momenta Pharmaceuticals (NasdaqGS:MNTA) revealed on Thursday the receipt of orphan drug designation from the US Food and Drug Administration (FDA) for its novel oncology candidate, necuparanib (formerly M402), for the treatment of pancreatic cancer.
Momenta Pharmaceuticals Receives Orphan Drug Designation for Necuparanib (Formerly M402) in Pancreatic Cancer
GlobeNewswire - Thu Jun 05, 7:10AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that its novel oncology candidate, necuparanib (formerly M402), has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.
Biotech Stocks Technical Data -- Research on Dynavax Technologies, Ironwood Pharma, Rigel Pharma, and Momenta Pharma
PR Newswire - Tue Jun 03, 6:30AM CDT
On Monday, June 02, 2014, the NASDAQ Composite ended at 4,237.20, down 0.13%, the Dow Jones Industrial Average finished the day 0.16% higher at 16,743.63, and the S&P 500 closed at 1,924.97, up 0.07%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 691.40, up 0.17%, and the index has advanced 3.37% in the last one month. Investor-Edge has initiated coverage on the following equities: Dynavax Technologies Corp. (NASDAQ: DVAX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA). Free technical research on DVAX, IRWD, RIGL and MNTA can be downloaded upon signing up at:
Supreme Court + Risky Drug Launch = Billions at Stake
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Fri May 30, 10:35AM CDT
Teva Pharmaceutical no stranger to the courts, is on a bit of a losing streak trying to protect its lead multiple sclerosis drug, Copaxone. Because the company focuses on low margin generic drugs, its branded MS drug brings in a roughly fifth of...
Momenta Pharmaceuticals Has Returned 14.0% Since SmarTrend Recommendation (MNTA)
Comtex SmarTrend(R) - Tue May 27, 5:09PM CDT
SmarTrend identified a Downtrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on March 3rd, 2014 at $14.80. In approximately 3 months, Momenta Pharmaceuticals has returned 13.96% as of today's recent price of $12.73.
Teva Pharmaceutical Industries Ltd. Gets a Taste of its Own Medicine
Brian Orelli, The Motley Fool - Motley Fool - Thu May 22, 5:30PM CDT
Last week, Teva Pharmaceutical failed in another effort to block generic versions of its multiple sclerosis drug Copaxone from being approved by the Food and Drug Administration. The company, which also makes generic drugs, requested that a judge...
Insider Trading Alert - MNTA, CSCO And ANSS Traded By Insiders
at The Street - Thu May 22, 10:45AM CDT
Stocks with insider trader activity include MNTA, CSCO and ANSS
Momenta Pharmaceuticals Slumps: MNTA Falls 16.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:55AM CDT
Momenta Pharma saw a big move last session, as the company’s shares fell by nearly 17% on the day.
